InSightec
Tomorrow's Operating Room, Today.

Treatments and non-invasive procedures
through MR-guided focused ultrasound



InSightec
Bringing therapy into focus

Company Profile

- InSightec was founded as a private company in Israel in 1999
- The company, active in the fields of Oncology, Gynecology and Neurology , develops a non-invasive MR guided operating system - ExAblate®
- ExAblate® enables the treatment of cancerous and benign tumors, currently treated only through invasive procedures.
- International GE Healthcare is a strategic partner of InSightec
- The company employs about 160 people
- The first of the company's products approved by the FDA is in the treatment of uterine fibroids. Since 2002 about 6000 patients worldwide have been treated successfully
- As of today, over 80 ExAblate® systems have been sold and installed in leading medical facilities around the world
- Untl March 31 2010 about $237 million dollars have been invested in InSightec: $130 million capital, approx. $86 million from customers and approx. $21 million from R&D grants
- Founder, CEO and President of the company is Dr. Kobi Vortman, with 30 years of experience in managing hi-tech companies (15 in the medical field)

The Evolution of Operations

From ancient times until the end of the 19th century

Body incision to remove the tumor

From the end of the 19th century until the middle of the 20th century

Minimal incision to remove the tumor

The 21st century

Non-invasive surgery

InSightec
Bringing therapy into focus

Recognition by the International Community

- The prestigious **Business Week** described InSightec's technology as "**one of 25 ideas for a changing world."**

- The **Wall Street Journal** awarded InSightec a **bronze medal for Technology Innovation**.

- **The European Union** awarded InSightec a prize for **"innovative products and service to mankind".**

- **The World Economic Forum** selected InSightec as one of its **"Technology Pioneers"**

The Future is Here: Robotic and Non-invasive Operation

- Non-invasive operation, no incision no anesthetization , no hospitalization
- Planning, treatment and monitoring process is done in real-time, making the treatment patient specific vs. statistically matched
- Procedure is significantly safer than invasive operations
- Significantly less side effects compared to alternative treatments
- Short recovery time and return to a full and active life within a day or two

InSightec
Bringing therapy into focus

The ExAblate System

InSightec
Bringing therapy into focus

How does ExAblate work?

The ExAblate system is a combination of:

- Focused Ultrasound heating the targeted tissue with an acoustic beam until the required temperature and tumor ablations is achieved
- MRI for constant imaging in real-time for planning, supervising and monitoring the course of treatment and its outcome
- The combined technology is called **MR guided Focused Ultrasound (MRgFUS)**



An effect similar to that of concentrating sun rays through a magnifying glass

InSightec
Bringing therapy into focus

Operating Rooms of the Future

Body System ExAblate 2000/2100

- A platform for the treatment of various medical indications with one system
- Customers can purchase a system customized to their needs that includes a required combination of treatment indications
- Can be easily upgradeable for any required future configuration , with no need to replace the system
- There are over 70 body systems installed worldwide

Brain system ExAblate 4000

- Operational platform for treating brain tumors and disturbances in the central nervous system
- 6 research systems are currently installed in leading hospitals worldwide

Benefits of Treatment through Focused Ultrasound

For Patients

- Non-invasive treatment W/O anesthetics
- No need for hospitalization after treatment
- No incisions, scars or ionized radiation
- Low complication rate compared to regular operations
- Back to normal activity within one day

For Doctors

- High level and safe treatment with minimal complications
- Comfortable treatment process for the "operating doctor" – no need for sterilization and hours of standing
- Reputation as a pioneer researcher in an innovative and promising field
- Ability to perform a wide range of treatments using one system
- A source for new patients

For Hospitals

- Competitive advantage – owning innovative technology
- An attraction for patients wishing to be treated with non-invasive technology – raising the number of procedures carried out in the hospital
- Saving treatment and hospitalization costs
- Lower treatment and re-hospitalization rate due to lack of complications

The Future Operating Room

Treatment of Uterine fibroids
Annual market in G7 - $3B

Treatment of bone metastasis
Annual market in G7 - $10B

Treatment of prostate cancer
Annual market in G7 - $15B

Treatment of breast cancer
Annual market in G7 - $10B



Treatment of liver cancer
Annual market in G7 - $5B

Brain treatments
Annual market in G7 - $75B

InSightec
Bringing therapy into focus

Uterine Fibroids

- Uterine Fibroid treatment procedures are among the most common in Gynecology after delivery procedures. Over 70% of women over the age of 30 have fibroids. One out of every four women suffers from symptomatic fibroids.
- Uterine fibroids can cause excessive bleeding, pressure on bladder, nerve pressure and pain, enlarged uterus, and may prevent pregnancy
- In the US, 200,000 Hysterectomies are carried out yearly due to symptomatic fibroids, costing $1.5B ,in the G7 countries $3B. Another 100,000 invasive procedures are also carried out.

ExAblate Treatment:

- Carried out in 204 hours W/O hospitalization
- Enables a return to normal activity within a day
- High safety profile and good results
- Worldwide regulatory and commercial approvals for treatment
- **Approx. 6000 patients treated so far**



First indication to have proved the technology and to receive CE and FDA, and the first to claim medical coverage.

Annual market size in G7 - $3B

InSightec
Bringing therapy into focus

Pain Caused by Bone Metastasis

- In the G7 countries about 920,000 new cancer patients are diagnosed with bone metastasis, about 65-75% of them will suffer from pain and for about 30% of those suffering from pain there is no treatable solution besides narcotic medication. About $10B are invested yearly in treating pain caused by bone metastasis.
- Current treatment plans include : radiation (typically 6-10 separate treatments), operation and medicinal treatment

ExAblate Treatment:

- In most cases – a single treatment of about 2 hours
- No ionized radiation – treatment can be repeated if necessary
- Immediate results – significant and on-going relief in pain within 2-3 days
- About 180 patients have been treated so far. CE in Europe, stage 3 FDA trial

The first Oncology indication to receive regulatory approval and based on existing medical coverage of radiation treatment

Annual market size in G7 - $10B

Prostate Cancer

- Prostate cancer is one of the most prevalent forms of cancer (1 out of 6 men in the western world)
- In the G7 countries about 400,000 new cases are diagnosed yearly
- Current treatments include: Prostatectomy, radiation, cryotherapy, and complementary hormone therapy
- These treatments cause a high percent of side effects: impotency (30%-90%) and incontinence (20%-70%)

ExAblate Treatments:

- Accurate and focused treatment with no iodized radiation
- Significant decrease in side-effects, back to normal activity within one day
- Beginning of clinical trial phase – two patients treated so far with excellent results



First oncology indication with a business blockbuster potential

Annual market size in G7 - $15B

Liver Cancer

- Liver cancer is characterized by primary and metastatic tumors
- Primary tumors:
  - Primary tumors are common in Africa, China and Southeast Asia (over 50% of all cancer cases)
  - Every year 600,000 new cases of primary cancer are diagnosed worldwide
- Metastatic tumors: The liver is the 2nd most common organ with metastatic cancer after the lungs. About 1 million patients a year worldwide
- Main types of treatment: Operation, chemotherapy and radiation
  - Surgical tumor removal is the only therapy treatment, but only 10-15% of patients are candidates for surgery
  - Estimated cost for G7 - $5B

ExAblate Treatment

- Non-invasive treatment, no iodized radiation
- Will enable treatment of non-anesthetized patients – the system corrects liver movement
- Enables treatment of single or multiple tumors
- Fast recovery
- About 10 patients have been treated



Annual market size in G7 - $5B

Oncology indication with a business blockbuster potential

InSightec
Bringing therapy into focus

Brain Tumors and Nervous System Diseases

- Treatment with the ExAblate 4000 system
- Treatment of a wide range of neurological and neurosurgical indications: brain tumors, central nervous system diseases (epilepsy, Parkinson, neuropathic pain) and stroke
- Annual estimated cost of treatment in G7 – $75B

ExAblate Treatment:

- No need to open skull
- Non iodized radiation – enabling repeated treatments
- Clinical trial is in initial stages:
  - Immediate results and significant and on-going relief in neuropathic pain, 12 patients treated so far
  - Tumors: 4 patients treated so far
  - Stroke indication is in animal testing phase

Annual market size in G7 - $75B

Treatment Approval Road Map



- The 2000 model is approved for uterine fibroid in the USA, Europe, Taiwan, Korea, Australia, New Zealand, Brazil, Mexico, Russia, Japan and Singapore. Approval for palliative treatment in bone cancer: In Israel, Europe, Korea, Brazil, Australia and New Zealand. Breast cancer treatment approval in: Korea, Australia and New Zealand.
- The 2100 model is approved in the USA, Europe and Israel according to the above indications
- Future approval dates are based on best assessments and past experience

InSightec
Bringing therapy into focus

Market Analysis (G7) by Indication

Market Potential Assessment in G7 countries

Indication	Annual Market Size (1)	Annual no. of Procedures	Market Size (no. of systems) (2)
Uterine Fibroids	$3B	600,000	4,000
Bone Metastasis	$10B	920,000	6,133
Prostate Cancer	$15B	400,000	2,667
Breast Cancer	$10B	433,000	2,887
Liver Tumors	$5B	600,000	4,000
Total	**$43B**	**2,953,000**	**19,687**
Brain (3)	$75B		

(1) According to public resources, described in the forecast

(2) Market size as far as no. of systems, calculated by 150 procedures per system per year

(3) Brain – including all neurological applications. Market size only

Patents and Scientific Publications on ExAblate

- 95 registered patents (39 in the USA, 56 in the ROW)
- 51 pending patents (25 in the USA, 26 in the ROW)
- Over 50 scientific papers published in journals on uterine fibroid treatment with MRI-guided focused ultrasound
- 4 published papers on pain treatment in bone metastasis
- 12 published papers on brain treatment
- 11 published papers on breast cancer treatment
- 11 chapters published in professional literature
- A dedicated book published on this topic
- 2 professional associations: ISTU and FUS Foundation



Competition

- The current standard treatment competing with ExAblate:
  - Surgery
  - Minimally invasive treatments
  - Radiation and medicinal treatments
- Focused ultrasound, ultrasound guided:
  - EDAP, focused surgery and several Chinese companies
- Focused ultrasound, MRI guided:
  - Philips is in the initial market penetration stages with a CE for Uterine Fibroids (50 treatments)
  - Siemens in collaboration with HAIFU is in initial clinical stages for regulation in China

Management Team

- **Dr. Kobi Vortman – President and CEO**
  Founder, Ph.D. in Electro Optics and over 30 years of experience in managing hi-tech companies, 15 of which in the medical field: Elbit Imaging, Diagsonics, Elscint Tech and others.
- **Oded Tamir – VP and COO**
  Founder, over 20 years of business experience
- **Amir Harel – VP and CFO**
  Chief Financial Officer, 16 years of experience in financial management of public companies: Tower Semiconductor, Elbit and others.
- **Dr. David Freundlich – VP Clinical R&D**
  Ph.D in Nuclear Physics and over 30 year of experience in R&D in medical systems: Elbit Imaging, Elscint and others.
- **Dr. Shuki Vitek – VP R&D**
  Ph.D in mathematics with vast experience in research, development and engineering
- **Yoav Medan – VP and Chief Systems Architect**
  Ph.D in Aeronautical Engineering and M.B.A in Business Administration, over 30 years of experience in all engineering fields, worked in IBM Research for many years
- **Haya Zarko - VP Human Resources**
  Over 25 years of experience in the field of HR in medical companies
- **Nadir Alikacem, VP Global Regulatory Affairs and CRO**
  Ph.D in Physics, vast experience in regulations and managing clinical trials
- **Lynn Golumbic - VP Marketing and Reimbursement**
  MBA in Marketing and Finance and vast knowledge in the field of reimbursement
- **Dr. Roni Yagel – VP Global Sales**
  Ph.D in Computer Science and vast experience in software management, marketing and sales
- **Dr. Yerucham Shapira - Software R&D Director**
  Ph.D in mathematics and computer science, leads the software development in the company
- **Baruch Avruch – VP Operations**
  Electrical Engineer with 20 years of experience in systems engineering and project management
- **Eyal Zadicario - Director, R&D and Neuro Programs**
  MSc in Aeronautical Engineering, vast knowledge in various fields of R&D and experience in leading technological and engineering projects
- **Dr. Arik Hanannel - Director of Clinical Research & Bone Program Manager**
  Medical Doctor and computer engineer responsible for leading the clinical research field in the company

Thank you for your attention





InSightec
Bringing therapy into focus